A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative ...

Celltrion's biosimilar Steqeyma, which mimics Johnson & Johnson's Stelara, received FDA approval for various conditions, marking the company's latest entry into the U.S. market as part of its growth ...

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.

Early diagnosis is vital to ensure people get on the right treatment path as soon as possible. Until now, there was no single ...

Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...

The dramatic rise is another peak in Teva's recovery over the past year and rewards investors after a long period of ...

Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The ...

Teva Pharmaceutical (NYSE: TEVA) and Sanofi (NASDAQ: SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for ...

Oil rose slightly in Asia. The market is awaiting the Fed's rate decision. An interest rate cut could support economic growth and oil demand, leading to a more bullish outlook for global crude oil ...